SEC Filing Summary: SIGA Technologies Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K, dated September 16, 2014, details SIGA Technologies, Inc.'s voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code filed in the Southern District of New York. The filing aims to preserve the company's ability to supply Tecovirimat, an antiviral smallpox drug, to the U.S. Strategic National Stockpile under a contract with the Biomedical Advanced Research and Development Authority (BARDA). SIGA intends to operate as a going concern during the bankruptcy proceedings.
Key Financial Metrics and Agreements
The filing does not provide specific revenue, profit, or cash flow figures for the reporting period. However, it outlines critical financial arrangements resulting from the bankruptcy filing:
- Debt Restructuring: SIGA entered into a Stipulation and Agreed Order with General Electric Capital Corporation (GE Capital) regarding its existing Loan Agreement.
- Cash Collateral: SIGA is permitted to continue using cash subject to a lien by GE Capital.
- Loan Obligations: SIGA must continue making regularly scheduled interest (at the non-default rate) and amortization payments on the term loan.
- Revolving Credit: The revolving loan commitment is terminated. SIGA must pay $70,000 to GE Capital in full satisfaction of amounts related to this termination.
- Liquidity Requirement: SIGA must maintain a minimum balance of $4 million in a specified account as collateral.
- Default Interest: SIGA and GE Capital reserve rights regarding whether default rate interest is payable; if determined payable, the amount (less the $70,000 payment) will be added to the loan obligations.
Material Changes and Legal Contingencies
The primary material change is the initiation of Chapter 11 bankruptcy proceedings. This action is a direct response to a pending Delaware Chancery Court proceeding initiated by PharmAthene, Inc. in 2006. On August 8, 2014, the Court ruled that PharmAthene is entitled to a lump sum damages award, with interest and fees, based on anticipated U.S. government purchases of SIGA's smallpox drug as of December 2006. The total judgment amount is unspecified but described as likely substantial. Enforcement of this judgment would jeopardize SIGA's viability. The Chapter 11 filing prevents immediate enforcement by PharmAthene and allows SIGA to pursue an appeal.
Outlook, Risks, and Unusual Items
Operational Outlook: SIGA has received Bankruptcy Court approval for "first-day" motions, allowing operations to continue during the Chapter 11 case to fulfill its BARDA contract.
Delisting Risk: On September 16, 2014, SIGA received notice from The NASDAQ Stock Market, LLC that its securities will be delisted due to the Chapter 11 filing. Unless an appeal is requested and successful, trading will be suspended on September 25, 2014. SIGA anticipates requesting an appeal, and the stock will remain listed pending the hearing outcome.
Risks: The company faces significant uncertainty regarding the final damages award from the PharmAthene litigation and the potential impact of delisting on its stock liquidity and investor base.
Investor Verification Checklist
- Verify the status of the appeal against the Delaware Chancery Court's August 8, 2014, opinion regarding PharmAthene damages.
- Confirm the outcome of SIGA's appeal of the NASDAQ delisting determination.
- Monitor the company's ability to maintain the required $4 million cash collateral balance.
- Review subsequent filings for updates on the Chapter 11 case plan and the resolution of the PharmAthene litigation.
- Assess the impact of the bankruptcy on the company's contract with BARDA for Tecovirimat supply.